Friday, September 30, 2022


Biotechnology News Magazine

Michael Klichinsky PharmD PhD Becomes New Chief Scientific Officer of Carisma Therapeutics

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Michael Klichinsky PharmD, PhD co-founded the company in 2016 following his foundational work at the University of Pennsylvania that led to the development of Carisma’s chimeric antigen receptor macrophage (CAR-M) technology.

“The entire Carisma team is thrilled and honored to have Mike assume the role of Chief Scientific Officer on behalf of the company and to continue driving our novel cell therapy technology,” shared Steven Kelly, President and Chief Executive Officer of Carisma. “Working alongside Mike for nearly five years, I continue to be impressed by his expertise and passion for the work that we do – and am confident that through his leadership of our organization’s research efforts, we will continue to see the benefits and impact of his thoughtful and critical approach to engineered cell therapies unfold.”

Michael Klichinsky PharmD, PhD, received his PhD in Pharmacology from the Perelman School of Medicine at the University of Pennsylvania, where he conducted his thesis work under the co-mentorship of Saar Gill, MD, PhD, and Carl June, MD – leading to the co-invention of engineered macrophages and the first-in-human CAR-M therapy CT-0508.

“I am thrilled to continue building upon the pioneering research Carisma is conducting with our engineered macrophage technology,” reflected Michael. “This is an exciting time for the science, as we expand our platform into engineering monocytes and iPSC derived myeloid cells. Additionally, we are excited to advance our work on the in vivo reprogramming of myeloid cells through our collaboration with Moderna.”

Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine